11:38 AM EDT, 09/10/2024 (MT Newswires) -- Sophia Genetics ( SOPH ) said Tuesday it will make available its liquid biopsy test MSK-ACCESS with SOPHiA DDM in 20 locations worldwide over the next 12 months, in collaboration with AstraZeneca ( AZN ) .

The liquid biopsy test, which was developed by Memorial Sloan Kettering Cancer Center, or MSK, combines the cloud-based offerings of the SOPHiA DDM platform with MSK's scientific and clinical expertise in cancer genomics.

Terms of the collaboration were not disclosed.

Shares of Sophia Genetics ( SOPH ) rose over 3% in recent trading, while AstraZeneca ( AZN ) added 0.4%.

Price: 3.83, Change: +0.14, Percent Change: +3.79